| DC67199 |
Virginiamycin M1
Featured
|
Virginiamycin M1 (Pristinamycin IIA; Ostreogrycin A), produced by Streptomyces virginiae, is an polyunsaturated macrocyclic lactone antibiotic and acts as a component of Virginiamycin (HY-112665). Virginiamycin M1 alone is against Staphylococcus aureus with a MIC of 0.25 μg/mL. |
|
| DC67200 |
FR179642 hydrate
Featured
|
FR179642 hydrate is the cyclic peptide nucleus of the lipopeptide antifungal FR901379 and an intermediate in the synthesis of the echinocandin antifungal FK463. |
|
| DC67201 |
Pneumocandin C0 (9CI)
Featured
|
Pneumocandin C0 is the isomer of Pneumocandin B0 (HY-17578) with antifungal activity, which is found by carrying out fermentations of Glarea lozoyensis at a high residual fructose concentration. |
|
| DC67202 |
Pneumocandin E0
Featured
|
|
|
| DC67203 |
ZERANOL
Featured
|
|
|
| DC67204 |
Chloroorienticin A
Featured
|
Chloroorienticin A (A82846B) is a glycopeptide antibiotic. Chloroorienticin A exhibits excellent activity against staphylococci and streptococci. |
|
| DC67205 |
Daunorubicin EP Impurity B
Featured
|
|
|
| DC67206 |
Cp2-S04
Featured
|
|
|
| DC67207 |
Flecainide hydrochloride
Featured
|
Flecainide hydrochloride is a potent and orally active antiarrhythmic agent widely used in the treatment of various cardiac arrhythmias. It belongs to the class IC antiarrhythmic drugs, which are known for their strong sodium channel-blocking properties. Flecainide hydrochloride primarily works by inhibiting the cardiac fast inward sodium current (INa) and the rapid component of the delayed rectifier potassium current (IKr), leading to a prolongation of the action potential duration (APD) in both ventricular and atrial muscle fibers. Its unique electrophysiological effects make it particularly effective in managing certain types of arrhythmias, including fetal tachycardias. |
|
| DC67208 |
INF 195
Featured
|
INF 195 is a potent and selective NLRP3 inflammasome inhibitor that has shown significant promise in preclinical studies for its ability to inhibit NLRP3-driven inflammatory responses, including macrophage pyroptosis and IL-1β release. By targeting the NLRP3 inflammasome, INF 195 has demonstrated therapeutic potential in conditions involving excessive inflammation, such as myocardial ischemia/reperfusion injury (IRI). |
|
| DC67209 |
Kif18A-IN-6
Featured
|
KIF18A-IN-6 (Compound 134) is a highly potent and orally active KIF18A inhibitor with significant potential for cancer therapy. Its ability to disrupt mitosis and induce apoptosis in cancer cells makes it a promising candidate for targeting chromosomally unstable tumors and advancing cancer research. |
|
| A852 |
Mavrilimumab
Featured
|
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. |
|
| A853 |
Trabikibart
Featured
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research. |
|
| A854 |
Anumigilimab
Featured
|
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation. |
|
| A855 |
CSL patent anti-G-CSFR
Featured
|
|
|
| A856 |
Quavonlimab
Featured
|
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody. |
|
| A857 |
Zalifrelimab
Featured
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling. |
|
| A858 |
SY18-VHH-11
Featured
|
|
|
| A859 |
CAT-2200
Featured
|
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A860 |
Ixekizumab
Featured
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis. |
|
| A861 |
UCB patent anti-IL-17
Featured
|
|
|
| A862 |
Anti-CTSS/Cathepsin S Antibody (Fsn0503h)
Featured
|
|
|
| A863 |
Quetmolimab
Featured
|
Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion. |
|
| A864 |
Lilly patent anti-Pan-ELR+
Featured
|
|
|
| A865 |
NI-0801
Featured
|
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A866 |
Eldelumab
Featured
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. |
|
| A867 |
Genentech anti-CXCL12
Featured
|
|
|
| A868 |
U.Penn. patent anti-PF4
Featured
|
|
|
| A869 |
Adakitug
Featured
|
Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001). |
|
| A870 |
ABX-IL8
Featured
|
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002). |
|
